## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence presented in the supplied abstract; no full text, figures, tables, or supplementary materials were provided
- **Shared manuscript claim summary** The authors report that the C620Y mutation in the androgen receptor DNA binding domain (AR DBD) causes conformational destabilization, altered dynamics, reduced DNA binding affinity, and disrupted nucleotide recognition, as inferred from parametric normal mode simulations, and propose a causal link to prostate cancer progression
- **Visible evidence base** Abstract text only; no quantitative data, simulation parameters, statistical analyses, or methodological details are available
- **Missing materials affecting confidence** Full manuscript, all figures and tables, simulation setup and parameters, force field details, trajectory lengths, convergence criteria, validation against experimental data, and any statistical treatment

## Reviewer
- **Overall assessment** The abstract addresses a clinically relevant question regarding the molecular mechanism of an AR DBD mutation in prostate cancer. The use of normal mode analysis to probe conformational and dynamic changes is reasonable in principle. However, the abstract presents qualitative descriptors without quantitative support, and the causal chain from simulation observations to disease progression is asserted rather than demonstrated. The evidence base is insufficient to evaluate the technical soundness of the simulations or the robustness of the conclusions. The work may be of interest to computational biologists and prostate cancer researchers, but the current abstract does not establish the case.
- **Who would be interested in the results, and why** Computational biophysicists studying protein dynamics and mutation effects, structural biologists focused on nuclear receptor DNA binding domains, and prostate cancer researchers interested in AR mutation mechanisms. The topic bridges molecular simulation and cancer biology, which could attract a cross-disciplinary audience if the technical basis were solid and the claims appropriately scoped.
- **Major strengths** The study targets a clinically relevant mutation with known functional consequences, which gives the work translational relevance. The use of multiple complementary analyses (RMSD, radius of gyration, solvent exposure, hydrogen bonding, hydrophobic interactions, RMSF, cross-correlation, PCA) suggests a systematic approach to characterizing conformational changes. The identification of a shifted DNA binding site is a specific and potentially testable prediction.
- **Major Concerns**
  - **Concern ID** R1-M1
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Technical soundness
  - **Claim pointer** The authors claim that parametric normal mode simulations reveal destabilization of the AR DBD upon C620Y mutation at unbound and bound levels
  - **Evidence pointer** Abstract; location not provided
  - **Concern** No methodological details are provided for the normal mode simulations. The term "parametric normal mode" is not standard in the field, and it is unclear what parameters were varied, what force field was used, how the system was prepared, what the simulation length was, and how convergence was assessed. Without this information, the reliability of the reported RMSD, RMSF, and PCA results cannot be evaluated.
  - **Why it matters** The entire conclusion rests on the validity of the simulation approach. If the method is nonstandard or improperly parameterized, all downstream observations are compromised. The abstract does not allow a reader to judge whether the simulations are physically meaningful.
  - **Resolution test** Provide full methodological details in the manuscript, including force field, system setup, equilibration protocol, simulation length, convergence criteria, and validation against experimental structures or known AR DBD dynamics. If the method is novel, a benchmark against established approaches is required.
  - **Concern ID** R1-M2
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Evidence strength
  - **Claim pointer** The authors claim a "comprehensive cause-and-effect relationship between mutational inactivation, reduced DNA-binding affinity and PC progression"
  - **Evidence pointer** Abstract; location not provided
  - **Concern** The abstract reports qualitative observations such as "unsettling RMSD curve," "more perpetuating stability," "inconsistent hydrophobic interactions," and "disrupted nucleotide pattern recognition" without any quantitative values, error estimates, or statistical comparisons. The leap from simulation-derived conformational changes to a causal relationship with prostate cancer progression is not supported by the data described.
  - **Why it matters** The central claim of the paper is a causal mechanism linking a mutation to disease. The abstract provides no experimental validation, no binding affinity measurements, no functional assays, and no clinical correlation. The causal language overreaches the evidence presented.
  - **Resolution test** Either temper the causal claims to reflect simulation-based hypotheses, or provide experimental validation such as DNA binding assays, cellular assays, or patient data that directly link C620Y to the proposed mechanism. Quantitative metrics with appropriate statistics must be reported for all simulation observables.
  - **Concern ID** R1-M3
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Reproducibility
  - **Claim pointer** The authors claim that the DNA binding site shifts from K581-R586 to K591-K610 in the mutant
  - **Evidence pointer** Abstract; location not provided
  - **Concern** This is a specific and important prediction, but the abstract provides no structural context, no residue numbering reference, no definition of how the binding site was determined, and no comparison to known AR DBD DNA contact residues. It is unclear whether this shift is a robust finding or an artifact of the simulation setup.
  - **Why it matters** A shifted binding site is a testable hypothesis with direct functional implications. If this claim is not rigorously supported, it could mislead subsequent experimental efforts.
  - **Resolution test** Show the structural basis for the binding site assignment, compare with experimental structures of AR DBD bound to DNA, and demonstrate that the shift is consistent across multiple simulation replicates or methods. Provide a clear definition of how binding sites are identified from the simulations.
- **Minor Comments**
  - **Concern ID** R1-m1
  - **Severity** Minor
  - **Axis** Clarity
  - **Affected element** Terminology
  - **Evidence pointer** Abstract; location not provided
  - **Issue** The term "parametric normal mode simulation" is unusual and not defined. Standard normal mode analysis is well established, and the qualifier "parametric" is ambiguous.
  - **Required correction** Define the term explicitly and explain how the approach differs from standard normal mode analysis, or use conventional terminology.
  - **Concern ID** R1-m2
  - **Severity** Minor
  - **Axis** Language precision
  - **Affected element** Qualitative descriptors
  - **Evidence pointer** Abstract; location not provided
  - **Issue** Phrases such as "unsettling RMSD curve," "more perpetuating stability," and "inconsistent hydrophobic interactions" are vague and not scientifically informative.
  - **Required correction** Replace qualitative descriptors with quantitative values, such as specific RMSD ranges, RMSF differences, and interaction counts, with appropriate statistical measures.
  - **Concern ID** R1-m3
  - **Severity** Minor
  - **Axis** Context
  - **Affected element** Background framing
  - **Evidence pointer** Abstract; location not provided
  - **Issue** The abstract states that C620Y causes "receptor inactivation with attenuated DNA binding" but does not cite the experimental source of this knowledge or explain how the simulation adds to this established finding.
  - **Required correction** Clearly state what is already known experimentally and what new information the simulations provide beyond the existing knowledge.
  - **Concern ID** R1-m4
  - **Severity** Minor
  - **Axis** Scope
  - **Affected element** Disease relevance
  - **Evidence pointer** Abstract; location not provided
  - **Issue** The connection between the simulation results and prostate cancer progression is stated but not elaborated. The abstract does not explain how reduced DNA binding affinity of a mutant AR would drive cancer progression, which is counterintuitive given that AR is typically activated in prostate cancer.
  - **Required correction** Provide a mechanistic rationale for how C620Y-mediated loss of DNA binding contributes to prostate cancer, or acknowledge the complexity of AR signaling in this context.

## Technical failings that need to be addressed before the case is established
- R1-M1: Absence of methodological detail for the simulation approach
- R1-M2: Lack of quantitative data and statistical support for all major claims
- R1-M3: Unsupported specific prediction of binding site shift without structural or comparative evidence

## Assessment against Nature-style criteria
- **Originality** The application of normal mode analysis to a specific AR DBD mutation is not clearly novel, as similar computational approaches are common in the field. The specific focus on C620Y may be of interest, but the abstract does not demonstrate a new conceptual or methodological contribution.
- **Scientific importance** The topic is clinically relevant, but the abstract does not establish that the findings advance understanding beyond what is already known experimentally about C620Y. The causal claim linking simulation to disease progression is not supported.
- **Interdisciplinary readership** The work could appeal to both computational and cancer biology audiences, but the abstract is written in a way that assumes familiarity with simulation jargon while lacking the quantitative detail that computational readers would expect.
- **Technical soundness** Cannot be assessed from the abstract. The method is not described, no validation is presented, and no quantitative results are reported. This is a critical deficiency.
- **Readability for nonspecialists** The abstract is accessible in its general structure but uses vague qualitative language that obscures rather than clarifies the findings. A nonspecialist would not be able to judge the strength of the evidence.

## Recommendation posture
Currently not established from the provided evidence. The abstract describes a computational study with potentially relevant findings, but the absence of methodological detail, quantitative results, and experimental validation prevents any assessment of technical soundness or scientific validity. The causal claims are not supported by the evidence presented. The manuscript would need substantial revision, including full methodological transparency, quantitative reporting, and appropriately scoped conclusions, before the case could be considered.

## Risk / unsupported claims
- The claim of a "comprehensive cause-and-effect relationship" between the mutation, reduced DNA binding, and prostate cancer progression is unsupported by the abstract evidence
- The specific binding site shift from K581-R586 to K591-K610 is unverifiable without structural data or methodological definition
- All qualitative descriptors of stability, flexibility, and interaction changes are unsupported without quantitative values
- The relevance of the simulation findings to actual prostate cancer biology is asserted but not demonstrated